<!DOCTYPE html>
<html>
<meta charset="UTF-8">
<head>
    <title>IFNG——IFNGR1 - PMID Details</title>
    <style>
        body {
            font-family: Arial, sans-serif;
            margin: 20px;
            line-height: 1.6;
            color: #333;
        }

        h1 {
            text-align: center;
            font-size: 2.5em;
            color: #2c3e50;
            margin-bottom: 20px;
        }

        /* Navbar Styles */
        nav {
            background-color: #2c3e50;
            padding: 10px 20px;
            box-shadow: 0 4px 6px rgba(0, 0, 0, 0.1);
            color: white;
            display: flex;
            justify-content: space-between;
            align-items: center;
        }

        nav .navbar-left, nav .navbar-right {
            display: flex;
            align-items: center;
        }

        nav a {
            color: white;
            text-decoration: none;
            margin: 0 15px;
            font-size: 1.1em;
            transition: color 0.3s ease;
        }

        nav a:hover {
            color: #f39c12;
        }

        nav .divider {
            color: #ecf0f1;
            margin: 0 10px;
        }

        /* Page Footer */
        footer {
            margin-top: 40px;
            padding: 10px 20px;
            background-color: #f7f7f7;
            color: #333;
            display: flex;
            justify-content: space-between;
            align-items: center;
        }

        /* Tab and Content Styles */
        .tab {
            display: flex;
            flex-wrap: wrap;
            justify-content: center;
            margin-bottom: 20px;
        }

        .tab button {
            padding: 10px 20px;
            margin: 5px;
            margin-bottom: 10px;
            cursor: pointer;
            background-color: #f4f4f4;
            border: 2px solid #ddd;
            border-radius: 5px;
            font-size: 1.1em;
            transition: background-color 0.3s ease;
            flex-basis: calc(10% - 10px);
            box-sizing: border-box;
        }

        .tab button:hover {
            background-color: #ecf0f1;
        }

        .tab button.active {
            background-color: #3498db;
            color: white;
            border-color: #2980b9;
        }

        .tabcontent {
            display: none;
            padding: 20px;
            margin-top: 10px;
            background-color: #ecf0f1;
            border-radius: 5px;
            box-shadow: 0px 0px 10px rgba(0, 0, 0, 0.1);
        }

        .tabcontent.active {
            display: block;
        }

        .tabcontent h2 {
            font-size: 2em;
            color: #2980b9;
        }

        .tabcontent p {
            font-size: 1.2em;
            line-height: 1.8;
        }

        /* Emphasize Title and Abstract */
        .title, .abstract {
            background-color: #f9f9f9;
            padding: 20px;
            margin: 10px 0;
            border-left: 5px solid #2980b9;
            box-shadow: 0 4px 6px rgba(0, 0, 0, 0.1);
        }

        .abstract {
            border-left: 5px solid #e74c3c;
        }
    </style>
    <script>
        function adjustTabStyle() {
            var tabCount = document.querySelectorAll('.tab button').length;
            var tabContainer = document.querySelector('.tab');

            if (tabCount > 10) {
                tabContainer.classList.add('small-tabs');
            }
        }

        function openTab(evt, tabId) {
            document.querySelectorAll(".tabcontent").forEach(tab => tab.style.display = "none");
            document.querySelectorAll(".tablinks").forEach(link => link.classList.remove("active"));
            document.getElementById(tabId).style.display = "block";
            evt.currentTarget.classList.add("active");
        }

        window.onload = adjustTabStyle;
    </script>
</head>
<body>
    <nav>
        <div class="navbar-left">
            <a href="">ConnectomeDB</a>
            <a href="https://comp.med.yokohama-cu.ac.jp/collab/connectomeDB/">Home</a>
            <a href="https://comp.med.yokohama-cu.ac.jp/collab/connectomeDB/database.html">Database</a>
        </div>
        <div class="navbar-right">
            <a href="https://www-user.yokohama-cu.ac.jp/~bioinfo/">YCU Bioinformatics Lab</a>
            <span class="divider">|</span>
            <a href="https://perkins.org.au/research/labs/cancer-program/systems-biology-and-genomics-overview/">Perkins Systems Biology & Genomics Lab</a>
        </div>
    </nav>

    <h1>PMID Details for IFNG——IFNGR1</h1>

    <div class="tab">
        <button class="tablinks active" onclick="openTab(event, 'tab10811850')">10811850</button><button class="tablinks " onclick="openTab(event, 'tab12165521')">12165521</button><button class="tablinks " onclick="openTab(event, 'tab10986460')">10986460</button><button class="tablinks " onclick="openTab(event, 'tab11250200')">11250200</button>
    </div>

    <div class="tabcontent" id="titleTab">
        <div class="title">
            <h2>Title</h2>
            <p>{{TITLE}}</p>
            <i> Journal:{{JOURNAL}}; Year Published:{{YEAR}}</i>   
        </div>
    </div>

    <div class="tabcontent" id="abstractTab">
        <div class="abstract">
            <h2>Abstract</h2>
            <p>{{ABSTRACT}}</p>
        </div>
    </div>

    
                <div id="tab10811850" class="tabcontent active">
                    <h2>In a novel form of IFN-gamma receptor 1 deficiency, cell surface receptors fail to bind IFN-gamma.</h2>
                    <h3>The Journal of clinical investigation; 2000</h3>
                    <p>Complete IFN-gamma receptor ligand-binding chain (IFNgammaR1) deficiency is a life-threatening autosomal recessive immune disorder. Affected children invariably die of mycobacterial infection, unless bone marrow transplantation is undertaken. Pathogenic IFNGR1 mutations identified to date include nonsense and splice mutations and frameshift deletions and insertions. All result in a premature stop codon upstream from the segment encoding the transmembrane domain, precluding cell surface expression of the receptors. We report herein two sporadic and two familial cases of a novel form of complete IFNgammaR1 deficiency in which normal numbers of receptors are detected at the cell surface. Two in-frame deletions and two missense IFNGR1 mutations were identified in the segment encoding the extracellular ligand-binding domain of the receptor. Eight independent IFNgammaR1-specific mAb's, including seven blocking antibodies, gave recognition patterns that differed between patients, suggesting that different epitopes were altered by the mutations. No specific binding of (125)I-IFN-gamma to cells was observed in any patient, however, and the cells failed to respond to IFN-gamma. The mutations therefore cause complete IFNgammaR1 deficiency by disrupting the IFN-gamma-binding site without affecting surface expression. The detection of surface IFNgammaR1 molecules by specific antibodies, including blocking antibodies, does not exclude a diagnosis of complete IFNgammaR1 deficiency.</p>
                    <p><a href="https://pubmed.ncbi.nlm.nih.gov/10811850/" target="_blank">[For more details, see PubMed]</a></p>
                </div>
                
                <div id="tab12165521" class="tabcontent ">
                    <h2>Lipid microdomains are required sites for the selective endocytosis and nuclear translocation of IFN-gamma, its receptor chain IFN-gamma receptor-1, and the phosphorylation and nuclear translocation of STAT1alpha.</h2>
                    <h3>Journal of immunology (Baltimore, Md. : 1950); 2002</h3>
                    <p>IFN-gamma contains a nuclear localization sequence that may play a role in the nuclear transport of activated STAT1alpha via a complex of IFN-gamma/IFN-gamma receptor (IFNGR)-1/STAT1alpha with the nuclear importer nucleoprotein interactor 1. In this study, we examine the mechanism of endocytosis of IFNGR-1 and the relationship of its nuclear translocation to that of STAT1alpha. In untreated WISH cells, both IFNGR-1 and IFNGR-2 were constitutively localized within caveolae-like microdomains isolated from plasma membrane. However, treatment of cells with IFN-gamma resulted in rapid migration of IFNGR-1, but not IFNGR-2, from these microdomains. Filipin pretreatment, which specifically inhibits endocytosis from caveolae-like microdomains, inhibited the nuclear translocation of IFN-gamma and IFNGR-1 as well as the tyrosine phosphorylation and nuclear translocation of STAT1alpha, but did not affect the binding of IFN-gamma to these cells. In the Jurkat T lymphocyte cell line, which does not express caveolin-1, nuclear translocation of IFNGR-1 and STAT1alpha were similarly inhibited by filipin pretreatment. Isolation of lipid microdomains from Jurkat cells showed that both IFNGR-1 and IFNGR-2 were associated with lipid microdomains only after stimulation with IFN-gamma, suggesting that the IFNGR subunits are recruited to lipid microdomains by IFN-gamma binding in lymphocytes (Jurkat) in contrast to their constitutive presence in epithelial (WISH) cells. In contrast, treatments that block clathrin-dependent endocytosis did not inhibit either activation or nuclear translocation of STAT1alpha or the nuclear translocation of IFN-gamma or IFNGR-1. Thus, membrane lipid microdomains play an important role in IFN-gamma-initiated endocytic events involving IFNGR-1, and the nuclear translocation of IFN-gamma, IFNGR-1, and STAT1alpha.</p>
                    <p><a href="https://pubmed.ncbi.nlm.nih.gov/12165521/" target="_blank">[For more details, see PubMed]</a></p>
                </div>
                
                <div id="tab10986460" class="tabcontent ">
                    <h2>Observation of an unexpected third receptor molecule in the crystal structure of human interferon-gamma receptor complex.</h2>
                    <h3>Structure (London, England : 1993); 2000</h3>
                    <p>Molecular interactions among cytokines and cytokine receptors form the basis of many cell-signaling pathways relevant to immune function. Interferon-gamma (IFN-gamma) signals through a multimeric receptor complex consisting of two different but structurally related transmembrane chains: the high-affinity receptor-binding subunit (IFN-gammaRalpha) and a species-specific accessory factor (AF-1 or IFN-gammaRbeta). In the signaling complex, the two receptors probably interact with one another through their extracellular domains. Understanding the atomic interactions of signaling complexes enhances the ability to control and alter cell signaling and also provides a greater understanding of basic biochemical processes.</p>
                    <p><a href="https://pubmed.ncbi.nlm.nih.gov/10986460/" target="_blank">[For more details, see PubMed]</a></p>
                </div>
                
                <div id="tab11250200" class="tabcontent ">
                    <h2>The structure and activity of a monomeric interferon-gamma:alpha-chain receptor signaling complex.</h2>
                    <h3>Structure (London, England : 1993); 2001</h3>
                    <p>Interferon-gamma (IFN-gamma) is a homodimeric cytokine that exerts its various activities by inducing the aggregation of two different receptors. The alpha chain receptor (IFN-gammaRalpha) is a high affinity receptor that binds to IFN-gamma in a symmetric bivalent manner to form a stable, intermediate 1:2 complex. This intermediate forms a binding template for the subsequent binding of two copies of the second receptor, beta chain receptor (IFN-gammaRbeta), producing the active 1:2:2 signaling complex.</p>
                    <p><a href="https://pubmed.ncbi.nlm.nih.gov/11250200/" target="_blank">[For more details, see PubMed]</a></p>
                </div>
                

    <footer>
        <span>© Copyright 2024, YCU Bioinformatics Laboratory</span>
        <span>Page built with <a href="https://quarto.org/">Quarto</a> by バイオインフォマティクス解析センター</span>
    </footer>
</body>
</html>
